Travel Industry to Benefit From Enhanced Flight Search and Booking From Cirium and Amadeus Deal
31.1.2023 16:00:00 EET | Business Wire | Press release
Cirium, the aviation analytics leader, has signed a deal with Amadeus to provide its advanced flight schedules data into the Amadeus Travel Platform, further enhancing the dataset available for flight search and bookings.
As one of the travel industry’s technology leaders, complete and timely data is essential for Amadeus to deliver high quality information to customers. The new deal means that Cirium’s comprehensive schedules data will be integrated into the Amadeus Travel Platform, benefitting many Amadeus clients in the travel space, including airlines, travel providers and more.
Jeremy Bowen, Cirium CEO said: “Combining two leaders in their respective fields in the travel industry, through the expansion of Cirium’s partnership with Amadeus, will further improve flight search and bookings, as well as enable the industry to unlock new market opportunities, maximize revenue and produce a more efficient experience for the traveler. Our new partnership goes beyond providing global flight schedules to the Amadeus Schedules Analytics tool. It enhances its industry-leading Travel Platform, allowing Cirium’s schedules data to enrich the quality of information for Amadeus customers.”
Sam Abdou, Executive Vice President, Air, Rail & Global Online, Amadeus said: “The expansion of our partnership with Cirium and further integration of its data into our multi-sourced air schedules data platform enriches our dataset and contributes to maintaining a high data accuracy and bookability for our customers.”
Amadeus is a leading travel distribution and technology partner to the industry, with a global presence, underpinned by local expertise. The company builds critical solutions that help airlines and airports, hotels and railways, search engines, travel agencies, tour operators, and other travel players to run their operations and improve the travel experience. Integrating data from Cirium’s advanced schedules database, which covers over 900 airlines globally and all aircraft types, means businesses with access to the Amadeus Travel Platform can make more accurate data-driven decisions.
Cirium’s schedules data is unrivalled in the aviation industry. The company has over 40 years’ experience in airline schedules and connections data. One of Cirium’s leading schedules analytics products, Cirium Diio Mi, covers 97% of all worldwide airline scheduled flights going back 20 years and looking forward by 11 months.
Find out more about Cirium Schedules.
ENDS
Notes to editors
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit cirium.com.
About Amadeus
Travel powers progress. Amadeus powers travel. Amadeus’ solutions connect travelers to the journeys they want through travel agents, search engines, tour operators, airlines, airports, hotels, cars and railways.
We have developed our technology in partnership with the travel industry for over 30 years. We combine a deep understanding of how people travel with the ability to design and deliver the most complex, trusted, critical systems our customers need. In 2019, we helped connect over 1.9 billion people to local travel providers in over 190 countries. We are one company, with a global mindset and a local presence wherever our customers need us.
Our purpose is to shape the future of travel. We are passionate in our pursuit of better technology that makes better journeys.
Amadeus is an IBEX 35 company, listed on the Spanish Stock Exchange under AMS.MC. The company has also been recognized by the Dow Jones Sustainability Index for the last ten years.
To find out more about Amadeus, visit www.amadeus.com.
Follow us on:
Facebook
Twitter
LinkedIn
YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005610/en/
Contact information
For media enquiries please contact:
Cirium PR: media@cirium.com
The PC Agency (UK and Europe): cirium@pc.agency
Juliett Alpha Media Relations (Americas): cirium@juliettalpha.com
TrainTracks (Japan): cirium@traintracks.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 09:53:00 EEST | Press release
In an industry first, Ant International launched a full stack of AI-native solutions for payment, account, FX, treasury and growth operations for global businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917771311/en/ Peng Yang, CEO of Ant International, introduced the company’s payment foundation model at Ant International's 2026 global merchant event The AI-native product suite is built on a 2-layered security architecture, and our 2 proprietary foundation models: a payment foundation model (Antom 3-in-1 Transformer), and a time-series transformer (TST) forecasting model for FX and liquidity (FalconTST). Underpinning the FinAI stack are also 2 major pillars for payment interoperability for the AI era: our Agentic Mobile Protocol (AMP) and a blockchain-based wholesale settlement platform (WhaleRTP). This round of sweeping product upgrade aims to support all businesses with an AI action plan to complete two critic
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health system resilience and improving patient outcomes. These efforts focus on locally led solutions that enhance health infrastructure, prepare the healthcare workforce and leverage innovation to sustain essential services for climate-vulnerable communities. “Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom